Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



DexCom Shares Plunged: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of DexCom (Nasdaq: DXCM  ) , which is developing an ambulatory glucose monitor for diabetes sufferers, closed down more than 18% after giving full-year guidance that may have disappointed investors. (We've seen it happen before.)

So what: Second-quarter results appear to have come in above estimates, though it's difficult to tell exactly what the Street was looking for. DexCom booked an $0.11-per-share loss on $21.4 million in overall revenue, $15.2 million of which was related product sales. Analysts were expecting a $0.12-per-share loss and $20.8 million in revenue. Whether they were counting all revenue or just product revenue isn’t clear, though I suspect the latter.

Now what: Why? In reiterating guidance during yesterday's call with analysts, management called for $67.5 to $72.5 million in just product revenue for the full year. Wall Street wanted $78.1 million of … some sort of revenue. Regardless, judging by the size of the selloff, this looks like a miss. Do you agree? Disagree? Weigh in using the comments box below.

Interested in more info on DexCom?Add it to your watchlist.

Fool contributorTim Beyers is a member of theMotley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim'sportfolio holdings andFoolish writings, or connect with him on Google+ or Twitter, where he goes by @milehighfool. You can also get his insightsdelivered directly to your RSS reader.

Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1533883, ~/Articles/ArticleHandler.aspx, 10/27/2016 11:39:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,203.51 4.18 0.02%
S&P 500 2,137.12 -2.31 -0.11%
NASD 5,238.57 -11.70 -0.22%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 11:22 AM
DXCM $76.88 Down -0.37 -0.48%
DexCom CAPS Rating: ***